Constellation Pharmaceuticals, Inc. (CNST) financial statements (2020 and earlier)

Company profile

Business Address 215 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments384115
Cash and cash equivalents334115
Short-term investments50 
Other undisclosed current assets33
Total current assets:387117
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment11
Restricted cash and investments00
Total noncurrent assets:122
TOTAL ASSETS:399119
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities129
Accounts payable76
Accrued liabilities00
Employee-related liabilities53
Debt3 
Other liabilities00
Other undisclosed current liabilities86
Total current liabilities:2315
Noncurrent Liabilities
Long-term debt and lease obligation38 
Long-term debt, excluding current maturities30 
Operating lease, liability9
Liabilities, other than long-term debt00
Deferred rent credit 0
Other liabilities00
Total noncurrent liabilities:390
Total liabilities:6215
Stockholders' equity
Stockholders' equity attributable to parent338104
Common stock00
Additional paid in capital657338
Accumulated other comprehensive loss(0) 
Accumulated deficit(319)(234)
Total stockholders' equity:338104
TOTAL LIABILITIES AND EQUITY:399119

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:0 
Operating expenses(86)(61)
Other undisclosed operating loss(0) 
Operating loss:(86)(61)
Nonoperating income11
Investment income, nonoperating32
Interest and debt expense(2)(0)
Loss from continuing operations before equity method investments, income taxes:(88)(60)
Other undisclosed income from continuing operations before income taxes2 
Loss from continuing operations before income taxes:(86)(60)
Income tax expense(0) 
Loss before gain (loss) on sale of properties:(86)(60)
Other undisclosed net income 0
Net loss attributable to parent:(86)(60)
Other undisclosed net loss available to common stockholders, basic(0) 
Net loss available to common stockholders, diluted:(86)(60)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(86)(60)
Comprehensive loss, net of tax, attributable to parent:(86)(60)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: